ENDRA Life Sciences Inc. (NDRA) Key Metrics
NDRA valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $7.1M
- Enterprise value
- $8.5M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 1.5 10-yr median 175.7
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- −0.08
NDRA key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsNDRA valuation Price multiples at each fiscal year-end price.
NDRA returns How much profit the business earns on the capital it uses.
NDRA per-share figures Results divided by the shares outstanding at year-end.
NDRA financial health Debt, liquidity and how easily interest is covered.
NDRA valuation history
NDRA returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
NDRA debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
NDRA cash returned to shareholders
NDRA price vs earnings per share
NDRA key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $3.6M | $7.0M | $6.34B | $13.75B | $2.48B | $1.26B | $1.10B | — | — | — |
| Enterprise value | $3.3M | $4.6M | $6.33B | $13.74B | $2.47B | $1.25B | $1.10B | — | — | — |
| Price / book | 1.6 | 2.7 | — | — | 229.8 | 175.7 | 231.6 | — | — | — |
| Earnings yield | −197.1% | −163.8% | −0.2% | −0.1% | −0.5% | −0.9% | −1.2% | — | — | — |
| Free cash flow yield | −145.8% | −105.6% | −0.2% | −0.1% | −0.5% | −0.9% | −0.8% | — | — | — |
| Dividend yield | — | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.4% | — | — | — |
| Shareholder yield (dividends + buybacks) | — | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.4% | — | — | — |
| Share price at fiscal year-end | $4.53 | $6.26 | $3,710.00 | $7,122.50 | $1,211.00 | $1,312.50 | $2,940.00 | $2,625.00 | $8,505.00 | — |
| Per share | ||||||||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — |
| Earnings per share | −$8.93 | −$10.25 | −$5.89 | −$6.83 | −$5.49 | −$12.22 | −$35.48 | — | — | — |
| Operating cash flow per share | −$6.59 | −$6.59 | −$5.59 | −$6.62 | −$5.44 | −$11.22 | −$22.90 | — | — | — |
| Free cash flow per share | −$6.61 | −$6.61 | −$5.61 | −$6.72 | −$5.46 | −$11.28 | −$23.02 | — | — | — |
| Cash per share | $0.97 | $2.88 | $1.66 | $2.53 | $4.62 | $7.53 | $16.46 | — | — | — |
| Book value per share | $2.87 | $2.28 | $3.31 | $3.73 | $5.27 | $7.47 | $12.70 | — | — | — |
| Tangible book value per share | $0.32 | $2.28 | $3.31 | $3.73 | $5.27 | $7.47 | $12.70 | — | — | — |
| Dividends per share | — | $0.00 | $0.00 | $0.00 | $0.06 | $0.41 | $11.25 | — | — | — |
| Capex per share | $0.02 | $0.01 | $0.02 | $0.10 | $0.02 | $0.05 | $0.12 | — | — | — |
| Debt per share | $0.63 | $0.67 | $0.23 | $0.28 | $0.39 | $0.80 | $2.06 | — | — | — |
| Shares outstanding | 787K | 1.1M | 1.7M | 1.9M | 2.0M | 960K | 375K | — | — | — |
| Change in shares outstanding | −29.9% | −34.3% | −11.5% | −5.7% | +113.2% | +155.9% | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −291.6% | −280.0% | −156.4% | −146.5% | −125.1% | −196.6% | −241.7% | −170.0% | −245.4% | — |
| Return on invested capital (ROIC) | −438.8% | −517.2% | −273.3% | −417.4% | −641.9% | — | — | — | — | — |
| Return on assets (ROA) | −169.2% | −205.4% | −125.5% | −119.0% | −103.8% | −147.1% | −184.8% | −146.8% | −162.6% | −567.9% |
| Return on tangible assets | −381.1% | −258.5% | −148.9% | −142.1% | −87.2% | −133.8% | −185.4% | −135.6% | −87.8% | −565.5% |
| Free cash flow margin | — | — | — | — | — | — | — | — | −941.0% | −255.2% |
| Financial health | ||||||||||
| Total debt | $492,352 | $754,139 | $394,403 | $546,631 | $796,094 | $769,342 | $773,267 | $23 | $0 | $949,976 |
| Cash & short-term investments | $762,365 | $3.2M | $2.8M | $4.9M | $9.5M | $7.2M | $6.2M | $6.5M | $5.6M | $144,953 |
| Net debt | −$270,013 | −$2.5M | −$2.4M | −$4.3M | −$8.7M | −$6.5M | −$5.4M | −$6.5M | −$5.6M | $805,023 |
| Debt / equity | 0.22 | 0.29 | 0.07 | 0.08 | 0.07 | 0.11 | 0.16 | 0.00 | 0.00 | — |
| Debt / assets | 0.13 | 0.17 | 0.06 | 0.06 | 0.06 | 0.09 | 0.11 | 0.00 | 0.00 | 1.94 |
| Current ratio | 1.29 | 5.67 | 3.36 | 5.00 | 7.83 | 8.32 | 3.15 | 7.13 | 6.93 | 0.14 |
| Quick ratio | 1.29 | 5.67 | 0.45 | 3.45 | 7.00 | 7.72 | 3.10 | 7.07 | 6.71 | 0.11 |
| Interest coverage | — | — | — | -611.0 | -43.1 | -49.5 | -4.6 | -12.4 | — | — |
| Working capital | $217,013 | $2.8M | $2.1M | $6.8M | $10.6M | $7.2M | $4.5M | $6.0M | $5.0M | −$1.2M |
| Invested capital | $2.0M | $85,025 | $3.2M | $2.9M | $2.1M | $711,347 | −$640,270 | −$223,144 | −$326,390 | −$88,744 |
| Tangible asset value | $250,160 | $2.6M | $5.7M | $7.2M | $10.8M | $7.2M | $4.8M | $6.2M | $5.3M | −$893,767 |
| Net current asset value | −$625,708 | $1.5M | $1.9M | $6.5M | $10.0M | $6.6M | $4.1M | $6.0M | $5.0M | −$1.2M |
| Graham net-net per share | −$1.06 | $1.19 | $0.63 | $2.15 | $3.42 | $6.48 | $10.41 | — | — | — |
| Capital allocation | ||||||||||
| Dividends paid | — | $5,233 | $840 | $7,790 | $121,071 | $395,551 | $4.2M | — | — | — |
| Share buybacks (net) | — | — | — | — | — | $0 | $0 | $0 | $0 | $0 |
| Capex / revenue | — | — | — | — | — | — | — | 1,619.7% | 2.2% | 1.5% |
| Capex / depreciation | 0.11 | 0.08 | 0.12 | 0.86 | 0.20 | 0.31 | 0.38 | 1.46 | 0.13 | 0.12 |
| Stock-based compensation / revenue | — | — | — | — | — | — | — | 22.2% | 0.3% | 44.7% |
| R&D / revenue | — | — | — | — | — | — | — | 76,489.6% | 549.2% | 96.1% |
| SG&A / revenue | — | — | — | — | — | — | — | 65,033.6% | 817.3% | 305.7% |
| Efficiency | ||||||||||
| Days sales outstanding | — | — | — | — | — | — | — | 4,501.1 | 7.1 | — |
| Days of inventory on hand | — | — | 3,490.0 | 3,061.1 | 1,524.1 | 776.5 | 274.3 | — | 244.8 | 107.6 |
| Days payables outstanding | — | 557.7 | 645.6 | 1,094.6 | 971.0 | 1,856.9 | 3,030.6 | — | 1,064.7 | 238.8 |
| Cash conversion cycle (days) | — | — | — | — | — | — | — | — | -812.8 | — |
| Receivables turnover | — | — | — | — | — | 0.00 | 0.00 | 0.08 | 51.33 | — |
| Payables turnover | — | 0.65 | 0.57 | 0.33 | 0.38 | 0.20 | 0.12 | 0.00 | 0.34 | 1.53 |
| Inventory turnover | — | — | 0.10 | 0.12 | 0.24 | 0.47 | 1.33 | 0.00 | 1.49 | 3.39 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.11 | 1.05 |
| Average receivables | — | — | −$2.6M | — | −$478,602 | $253,774 | $131,086 | $76,137 | $6,850 | — |
| Average payables | $326,326 | $315,042 | $487,181 | $702,506 | $596,981 | $840,670 | $954,952 | $705,866 | $504,002 | $154,344 |
| Average inventory | — | — | $2.6M | $2.0M | $937,099 | $351,531 | $86,443 | $125,562 | $115,892 | $69,554 |
| Intangibles / total assets | 52.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from NDRA's annual financial statements (latest annual report filed March 31, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
NDRA valuation and financial ratios
ENDRA Life Sciences earned a return on equity of −291.6% and a return on invested capital of −438.8% in fiscal 2025. It ended the year with $0.5 million of debt and $0.8 million in cash and short-term investments, a net cash position of $0.3 million.
See the NDRA income statement, the NDRA chart for price history, or the NDRA stock overview for the latest quote and news.
NDRA key metrics FAQ
What is ENDRA Life Sciences's return on equity?
ENDRA Life Sciences's return on equity (ROE) was −291.6% in fiscal 2025: net income of -$7.0 million on average shareholders' equity of $2.4 million.
What is ENDRA Life Sciences's ROIC?
ENDRA Life Sciences's return on invested capital was −438.8% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does ENDRA Life Sciences have?
ENDRA Life Sciences had total debt of $0.5 million at the end of fiscal 2025, a debt-to-equity ratio of 0.22 and more cash than debt.
What is ENDRA Life Sciences's free cash flow yield?
ENDRA Life Sciences generated -$5.2 million of free cash flow in fiscal 2025, a free cash flow yield of −145.8% on its market value at year-end ($3.6 million).
What is ENDRA Life Sciences's current ratio?
ENDRA Life Sciences's current ratio was 1.29 at the end of fiscal 2025: current assets were 1.29 times current liabilities.